Application of morindae officinalis oligosaccharide pentasaccharide to preparation of drug for treating myocardial ischemia and reperfusion injury

A Morinda officinalis oligosaccharide and reperfusion injury technology, which is applied in the field of medicinal application of plant extracts, can solve the problems of aggravating ischemic myocardial injury and intramyocardial hemorrhage, and achieves the effects of stable properties, controllable quality and simple extraction methods.

Inactive Publication Date: 2014-03-19
冯国清 +1
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Thrombolysis, coronary artery bypass grafting, and coronary intervention are effective methods for the treatment of acute myocardial infarction. These methods can recanalize the blocked coronary artery, but timely reperfusion of myocardial ischemia can save some damaged but not yet necrotic myocardium. cells, may also aggravate ischemic myocardium damage, manifested as accelerated necrosis of myocardial cells, cell swelling, formation of muscle fiber contractile bands, intramyocardial hemorrhage and no perfusion, and severe reperfusion arrhythmias may also occur

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of morindae officinalis oligosaccharide pentasaccharide to preparation of drug for treating myocardial ischemia and reperfusion injury
  • Application of morindae officinalis oligosaccharide pentasaccharide to preparation of drug for treating myocardial ischemia and reperfusion injury
  • Application of morindae officinalis oligosaccharide pentasaccharide to preparation of drug for treating myocardial ischemia and reperfusion injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Preparation of Morinda officinalis oligosaccharide 4, 5, 6 polysaccharide monomer:

[0048] (1) Dissolve 10g of Morinda officinalis extract in 80ml of H 2 O, and freeze-dried.

[0049] (2) Add 100 ml of pyridine to 8.3 g of the freeze-dried product, and add 100 ml of anhydrous acetic acid while stirring at a temperature of 0°C.

[0050] (3) After stirring for 24 hours in a greenhouse state, the excess medium was removed by a decompression method.

[0051] (4) Add CHCl to the remaining part 3 , washed with saturated soda water and saturated saline.

[0052] (5) After drying with magnesium sulfate, remove CHCl under reduced pressure 3 .

[0053] (6) Separately purify by compound purification method (developing solvent: toluene: ethyl acetate (Toluene: Ethyl acetate) = 2:1 → 1:1 → 1:2 → 1:3 → 1:5). 623 mg of acetylated Hex4 monomer (Hex4 perAc) was extracted. 623 mg of acetylated Hex5 monomer (Hex5 perAc) was extracted. 74 mg of acetylated Hex6 monomer (Hex6 perAc)...

Embodiment 2

[0064] (1) Isolated endothelial cells and whole animal experiments

[0065] In the experimental system of neonatal rat cardiomyocytes, newborn (1-3d) SD / Wistar rats were used, and the heart was taken as primary cardiomyocyte culture, which were divided into normal control group, hypoxia-reoxygenation injury (H / R) model group, H / R+positive drug (Di'ao Xinxuekang, 0.7g·L -1 ) control group, H / R+Hex4 (42nmol·ml -1 ), Hex5 (30nmol·ml -1 ), Hex6 (22nmol·ml -1 )each group. The cardiomyocyte morphology and cardiomyocyte ultrastructure were used as the main evaluation indexes to observe the protective effect of Morinda officinalis 4, 5, and 6 glycans on cardiomyocytes.

[0066] In the experimental system of human umbilical vein endothelial cell (HUVEC) angiogenesis model, it was divided into normal control group, H / R model group, H / R+positive drug (Shexiang Baoxin pill, 2g·L -1 ) control group, H / R+Hex4 (42nmol·m1 -1 ), Hex5 (30nmol·ml -1 ), Hex6 (22nmol·ml -1 )each group. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a morindae officinalis extract and morindae officinalis oligosaccharide pentasaccharide to preparation of a drug for treating myocardial ischemia and / or reperfusion injury and promoting therapeutic angiogenesis. The myocardial ischemia and reperfusion injury belong to secondary injury brought to an organism when the hemoperfusion of myocardium is stopped or poor, i.e., after the myocardium is subjected to ischemia, hypoxia injury, circulation reinstitution and blood supply recovery. The morindae officinalis extract and the morindae officinalis oligosaccharide pentasaccharide both play a role in protecting an in-vivo rat myocardial ischemia reperfusion injury model and an in-vitro purification cultured neonatal rat myocardial cell hypoxia / reoxygenation injury model, and can be used for remarkably reducing the myocardial infarction area and the incidence rate of reperfusion arrhythmias, effectively protecting the form of a myocardial cell and relieving the injury of hypoxia / reoxygenation to the myocardial cell. The therapeutic angiogenesis promotion means that the aims of recovering the blood supply of ischemic myocardium and improving the heart function are achieved through increasing the functional coronary artery branch or side branch under the irritation actions of some methods, including the therapeutic actions of some drugs.

Description

technical field [0001] The invention relates to the field of medicinal applications of plant extracts, in particular to the application of Morinda officinalis oligosaccharides in the preparation of anti-myocardial ischemia and reperfusion injury drugs. Background technique [0002] Coronary atherosclerotic heart disease (CAD), referred to as coronary heart disease, also known as ischemic heart disease, is a common cardiovascular disease in humans and the most important fatal cardiovascular disease in adults. Acute myocardial infarction caused by coronary heart disease is the main cause of high morbidity and mortality of cardiovascular diseases. The incidence of coronary heart disease continues to increase, and the younger trend is obvious. Coronary heart disease is clinically manifested as severe myocardial ischemia, which seriously threatens human health. Mortality and long-term prognosis in patients with coronary heart disease are related to left ventricular function det...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/702A61K31/715A61P9/10A61P9/00C07H3/06C07H1/08
Inventor 冯国清姚闵胡香杰赵胜张贺鸣杨景柯王奎鹏于爽察雪湘孟祥光吴瑶焦平利王宁刘茜徐君玲张晓宁郭婷婷王涵澄
Owner 冯国清
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap